Clinical Trials Browser

Phase 3 × sabatolimab × 90 days × Clear all

NCT04266301 2026-01-13

STIMULUS-MDS2

Phase 3 Terminated

530 enrolled 29 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic